Cancer – one of the most feared and dreaded diseases. It is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2018, in the US alone. The World Health Organization has estimated the number of new cancer cases, reported across the globe, to rise by 70% over the next 20 years. Years of research has yielded several potential treatment options, such as chemotherapy, surgery, and radiation therapies. However, these methods continue to demonstrate limited efficacy in late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, have severe detrimental effects on patients’ quality of life.
developments in genomic analysis and advances in bioinformatics have enabled
the adoption of more personalized treatment approaches, such as neoantigen
targeted therapies. Cancer neoantigens is a term used to refer to a subset of
antigens encoded by tumor-specific, mutated genes, which have not previously
been recognized by host’s immune system. These are considered to be potential
biological targets that can be used to augment the therapeutic value of a
number of cancer immunotherapies, including immune checkpoint inhibitors and
cancer vaccines, having demonstrated the capability to elicit strong T-cell
mediated immune response. Currently, several neoantigen-based therapies are
being investigated in combination with various immune checkpoint inhibitors,
such as atezolizumab, durvalumab, ipilimumab and nivolumab. In fact, multiple
such initiatives by start-ups are backed by venture capital firms and other
and Preclinical Pipeline of Neoantigen Targeted Therapies
Presently, over 150 neoantigen targeted therapies are being evaluated for advanced cancer indications and are designed for delivery via different routes of administration.
Want additional details on the pipeline?
It is just a click
Number of Patents are Suggestive of the Widespread Research in this Domain
Industry and non-industry players, alike, are carrying out extensive research on neoantigen targeted therapies across a wide spectrum of indications. The field has seen a significant rise in the number of patents over the past decade, with the United States of America leading the way in terms of the total number of patents filed / granted.
highlights the rise in the interest of industry / non-industry stakeholders in
this emerging domain
to know about the most cited patents related to neoantigen targeted therapies.
are Betting their Money on this Novel Approach
Realizing the untapped opportunity in this emerging segment, several investors have invested in the initiatives of various therapy developers over the past 5 years. In fact, this upcoming segment of anti-cancer therapy has received a funding of more than USD 7 billion between 2014 and 2019.
increase in funding activity in recent years is proof of the fact that
neoantigen targeted therapies are the future of cancer immunotherapy. To get an
elaborate list of funding instances in this segment, please click here.
all the developments made in the field of medical science in the 21st
century, there still exists a lacuna when it comes to promising anti-cancer
therapies. Existing therapeutic modalities have failed to curb the menace of
ever-increasing cancer population worldwide. In such grime circumstances,
neoantigen targeted therapies bring a new ray of hope to treat cancer without
any severe adverse events.
further information on this emerging domain, check out the report here.